Loading clinical trials...

Transoral Endoscopic Thyroidectomy by Vestibular Approach (TOETVA) | Clinical Trials | Clareo Health

RECRUITINGNA

Transoral Endoscopic Thyroidectomy by Vestibular Approach (TOETVA)

Transoral Endoscopic Thyroidectomy by Vestibular Approach (TOETVA) Compared to Conventional Thyroidectomy by Cervical Approach: a Randomized Clinical Trial

NCT05412680•Fábio de Aquino Capelli

View on ClinicalTrials.gov

Summary

Prospective study carried out with ICESP (instituto do Câncer do Estado de São Paulo) patients with thyroid disease with surgical indication

Detailed Description

Prospective study carried out with ICESP patients with thyroid disease with surgical indication, according to the aforementioned inclusion criteria, totaling 60 cases, which will be randomized into two groups: * Conventional Thyroidectomy (30 patients) * Transoral Endoscopic Thyroidectomy By Vestibular Approach (30 patients)

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•history of hypertrophic scarring and/or motivation to avoid cervical scarring,
•maximum diameter of the thyroid \< 10 cm and of the dominant nodule \< 6 cm,
•estimated thyroid volume \< 45 ml
•benign lesion (multinodular goiter, cyst),
•indeterminate nodule (Bethesda III or IV),
•suspicious nodule for well-differentiated thyroid carcinoma (Bethesda V and VI) \< 2 cm

Exclusion Criteria

•history of previous surgery or irradiation in the head and neck region and superior mediastinum
•evidence of clinical hyperthyroidism
•preoperative recurrent nerve palsy
•lymph node metastasis
•extra-thyroid extension
•plunging goiter
•oral abscess

Locations (1)

ICESP

São Paulo, São Paulo, Brazil

Key Dates

Start Date

May 25, 2022

Primary Completion Date

December 31, 2024

Completion Date

December 31, 2024

Last Updated

May 14, 2024

Enrollment

ESTIMATED participants

Conditions

Thyroid DiseasesThyroid Cancer

Interventions

TOETVA

PROCEDURE

conventional thyroidectomy

PROCEDURE

Contacts

Fabio Capelli, phd

CONTACT

55 11 98292-2288 fabiocapelli81@gmail.com

The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma

NCT06316895

Papillary Thyroid Cancer

View study

RECRUITINGPHASE3

Contribution of ICG Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy

NCT04785443

Thyroid Diseases

View study

RECRUITINGPHASE2

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 14, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Transoral Endoscopic Thyroidectomy by Vestibular Approach (TOETVA)

Inclusion Criteria

Exclusion Criteria

The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma

Contribution of ICG Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total Thyroidectomy

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

Adjuvant Radiotherapy in High Risk Locally Advanced DTC

RW Study of Adjuvant Radiotherapy in Locally Advanced Thyroid Cancer

F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer